ライフサイエンスコーパス: multidrug

1 te three novel concepts to aid the design of multidrug adaptive therapies.

2 treatment cycles provides a path forward for multidrug adaptive therapy.

3 nceptual advances provide a path forward for multidrug adaptive therapy.

4 benefits noted with bedaquiline treatment in multidrug and extensively drug-resistant tuberculosis HI

5 ites, degradation of aromatic compounds, and multidrug and heavy metal resistance.

6 Multidrug and toxic compound extrusion (MATE) transporte

7 Three transporters, belonging to both the multidrug and toxic compound extrusion and ATP binding c

8 transporter, the solute carrier (SLC) human multidrug and toxin extrusion protein 1 (hMATE1, SLC47A1

9 ic cation transporters 1-3 (hOCT1-3) and the multidrug and toxin extrusion proteins 1 and 2-K (hMATE1

10 Our results suggest that hOCT2 and human multidrug and toxin extrusion proteins 1 and 2-K are inv

11 robe for OCT1 and OCT2 and MATE1 and MATE2K (multidrug and toxin extrusion proteins) in clinical stud

12 GaMF1 is bactericidal and is active against multidrug- as well as bedaquiline-resistant strains.

13 unusual flexibility in the coupling between multidrug binding and deprotonation in MdfA, but the mec

14 f a MdfA mutant E26T/D34M/A150E, wherein the multidrug-binding and protonation sites were revamped, s

15 A multidrug chemotherapeutic regimen FOL-F-IRIN-OX (combin

16 tic leukaemia enrolled in clinical trials of multidrug chemotherapy done between Oct 3, 2000, and Aug

17 tuberculosis (TB) and co-morbidities involve multidrug combination therapies.

18 Most concerning are the reports of multidrug drug resistance.

19 They participate in multidrug efflux and cell wall biogenesis to transform b

20 ism of drug export and inhibition of a major multidrug efflux pump and the directive role of its dyna

21 including the emhABC operon encoding a major multidrug efflux pump.

22 Resistance-nodulation-division (RND) type multidrug efflux pumps have been demonstrated to convey

23 The overexpression of multidrug efflux pumps is an important mechanism of clin

24 Overexpression of multidrug efflux pumps often creates broad-spectrum resi

25 Multidrug efflux pumps present a challenge to the treatm

26 It uses multidrug efflux pumps, including the MexAB-OprM pump, f

27 Multidrug efflux systems belonging to the resistance-nod

28 ABCB1 (P-glycoprotein/MDR1) is a multidrug efflux transporter that has previously been in

29 is Schu S4 strain for their contributions to multidrug efflux, suppression of innate immune responses

30 ound that each TolC ortholog participated in multidrug efflux, with overlapping substrate specificiti

31 lasma, (ii) gene W903_1820, encoding a small multidrug export family protein, contributes significant

32 for hydrophilic molecules, analogous to the multidrug exporters of the ABC transporter family, which

33 gemcitabine-based regimens may benefit from multidrug immunotherapy.See related commentary by Carpen

34 roduce small colonies that exhibit heritable multidrug increases in minimal inhibitory concentrations

35 s with flexible pharmacokinetic profiles and multidrug interaction curves that are estimated from dat

36 s with flexible pharmacokinetic profiles and multidrug interaction curves that are estimated from dat

37 Multidrug (MDR) efflux pumps are ancient and conserved m

38 The prototypic multidrug (Mdr) transporter MdfA from Escherichia coli e

39 the bacterial major facilitator superfamily multidrug-proton antiporter LmrP in Lactococcus lactis a

40 of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputu

41 Pyrazinamide has been a mainstay in the multidrug regimens used to treat tuberculosis.

42 air, electron transfer, and a component of a multidrug resistance (MDR) efflux pump were concluded to

43 he chemotherapeutic to overcome both BBB and multidrug resistance (MDR) glioma cells while providing

44 Multidrug resistance (MDR) in cancer arises from cross-r

45 Multidrug resistance (MDR) of pathogens is an ongoing pu

46 Multidrug resistance (MDR) represents a global threat to

47 vels of GRP78 protein in cancer cells confer multidrug resistance (MDR) to therapeutic treatment.

48 lied this approach to a cellular reaction of multidrug resistance (MDR) transport, which was followed

49 We reported the frequency of multidrug resistance (MDR)(resistance to ampicillin, cot

50 r treatment approach, suffers seriously from multidrug resistance (MDR), generally caused by innate D

51 glycoprotein (Pgp), a transporter conferring multidrug resistance (MDR).

52 mental biocides, transporters from the small multidrug resistance (SMR) family drive the spread of mu

53 -bound ABC transporter PfMDR1 (P. falciparum multidrug resistance 1 transporter).

54 transporter (PfCRT) is a key contributor to multidrug resistance and is also essential for the survi

55 addressed the causal association between HIV multidrug resistance and mortality, excluding factors on

56 nofluorescence analyses confirmed that MRP3 (multidrug resistance associated protein 3), which was hi

57 ruginosa, MexAB-OprM plays a central role in multidrug resistance by ejecting various drug compounds,

58 Multidrug transporters prompt multidrug resistance by exporting different therapeutics

59 resistance (SMR) family drive the spread of multidrug resistance cassettes among bacterial populatio

60 o studies were performed in BDL rats and the multidrug resistance gene 2 knockout (Mdr2(-/-) ) mouse

61 ation and T-cell activation while repressing multidrug resistance genes and cancer-related genes, the

62 Bacterial virulence and the spread of multidrug resistance have previously been linked to toxi

63 umps play a key role in inherent and evolved multidrug resistance in bacteria.

64 pporting the potential of CXL146 to overcome multidrug resistance in cancer treatment.

65 ansporter that was shown to confer low-level multidrug resistance in cancer.

66 stromal cells can promote tumorigenesis and multidrug resistance in prostate or breast cancer cells.

67 Multidrug resistance in the E. coli isolates collected (

68 ssette family, is one of the major causes of multidrug resistance in tumors.

69 Moreover, as multidrug resistance is common among S. maltophilia isol

70 Multidrug resistance is one major challenge to cancer tr

71 treatment enriched for strains that acquired multidrug resistance loci, encoding enzymes that confer

72 mily of efflux pumps have been implicated in multidrug resistance of this species complex.

73 The rapid increase of multidrug resistance poses urgent threats to human healt

74 ABCB1 encodes Multidrug Resistance protein (MDR1), an ATP-binding cass

75 or (PXR) was observed together with ApoE and multidrug resistance protein 1 (MDR1) membrane transport

76 Multidrug resistance protein 1 (MRP1) is an ABC exporter

77 harmacological inhibition with JZL184 in the multidrug resistance protein 2 knockout (Mdr2(-/-) ) mou

78 ngiocyte proliferation and liver fibrosis in multidrug resistance protein 2 knockout (Mdr2KO) mice as

79 s of healthcare-associated infections (HAI); multidrug resistance reduces available options for antib

80 e of such polymer-drug conjugates to reverse multidrug resistance through P-gp inhibition and to miti

81 Multidrug resistance to rifampicin and dapsone was obser

82 ve limited or no treatment options, owing to multidrug resistance(6).

83 eruginosa adapts to the CF lung, can develop multidrug resistance, and can form biofilms.

84 of transcription factors is associated with multidrug resistance, our aim was to evaluate whether th

85 Previously identified as a key mediator of multidrug resistance, the drug efflux behavior of P-glyc

86 Multidrug resistance-1 (MDR1) acts as a chemotherapeutic

87 Multidrug resistance-associated protein 1 (adenosine tri

88 breast cancer resistance protein (BCRP), and multidrug resistance-associated protein 2 (MRP2) at the

89 malignant lesions, we aim to investigate the multidrug resistance-associated protein 4 (MRP4)-depende

90 CK19 also positively regulated multidrug resistance-associated protein 4 expression at

91 d that androgen glucuronides are effluxed by multidrug resistance-associated proteins 2 and 3.

92 s resistant to TCS exhibited higher rates of multidrug resistance.

93 ddress the global health need and burgeoning multidrug resistance.

94 or roles in drug pharmacokinetics and cancer multidrug resistance.

95 ounds and have been implicated in conferring multidrug resistance.

96 might be clinically relevant to the rise of multidrug resistance.

97 zoyl]benzoic acid, an inhibitor of the ABC-B/multidrug resistance/P-glycoprotein subfamily of transpo

98 e niche-adaptive accessory traits, including multidrug resistance; 3) the accessory genome of the meg

99 We identified multidrug-resistance (MDR)-associated clade 4.3.1 as the

100 Multidrug-resistance among E.coli causing device- and pr

101 This study aimed to evaluate the prevalence, multidrug-resistance traits, PCR-detection of virulence,

102 Multidrug resistant (MDR) bacteria are a global threat w

103 s new avenues for diagnosis and treatment of multidrug resistant (MDR) bacterial infections.

104 Multidrug resistant (MDR) carbapenemase-producing (CP) K

105 study, we aimed to isolate and characterize multidrug resistant (MDR) E. coli in raw chicken meat sa

106 Multidrug resistant (MDR) strains of Acinetobacter bauma

107 n half (53.8%; 242/450) of NTS isolates were multidrug resistant (MDR; resistant to >=3 antimicrobial

108 estigated draft genomes of phage susceptible multidrug resistant A. baumannii strains from Thailand.

109 rently in development as an oral therapy for multidrug resistant and carbapenem-resistant Enterobacte

110 monas aeruginosa infections are increasingly multidrug resistant and cause healthcare-associated pneu

111 e countries, it has since the 1990s reported multidrug resistant and extensively drug resistant (XDR)

112 Infections caused by multidrug resistant bacteria represent a therapeutic cha

113 cs, and are a major disseminating source for multidrug resistant bacteria.

114 e compounds for the selective elimination of multidrug resistant cancer cells, setting the stage for

115 ding pocket substitution discovered within a multidrug resistant clinical isolate modifies the plasti

116 address the critical medical need created by multidrug resistant Gram-negative bacteria.

117 Multidrug resistant Gram-negative bacterial infections a

118 ibiotic for the treatment of a wide range of multidrug resistant Gram-negative bacterial infections,

119 last-resort antibiotic for the treatment of multidrug resistant Gram-negative bacterial infections.

120 ROR1's potential as a therapeutic target for multidrug resistant malignancies.

121 antibiotics, especially in the treatment of multidrug resistant pathogens.

122 in Ecc lineage 1, which had a higher rate of multidrug resistant phenotype (23/54 [43%]) relative to

123 was released basolaterally, in part through Multidrug Resistant Protein transporters, taken up by fi

124 mportance of polymyxins and the emergence of multidrug resistant strains(5), our understanding of the

125 has been faced with an emerging threat from multidrug resistant TB (MDR-TB).

126 two MTBC strains isolated from patients with multidrug resistant tuberculosis, representing an as-yet

127 s, ST1193-H64 isolates were more extensively multidrug resistant, whereas their virulence genotypes w

128 agnosed with a second episode of TB that was multidrug resistant.

129 ficult to treat, as K. pneumoniae has become multidrug resistant.

130 ogens were identified, none were found to be multidrug resistant.

131 high rates of AMR, with 51.9% (28/54) being multidrug-resistant (MDR) and 53.6% of these (15/28) bei

132 Multidrug-resistant (MDR) bacteria that are commonly ass

133 cular promise for preventing and controlling multidrug-resistant (MDR) bacterial infection via eradia

134 ctions caused by carbapenem-resistant and/or multidrug-resistant (MDR) Gram-negative bacteria in clin

135 blue light ([aBL] 405 nm wavelength) against multidrug-resistant (MDR) Gram-negative bacteria in vitr

136 Treatment options for multidrug-resistant (MDR) gram-negative infection are gr

137 new antibiotic classes with activity against multidrug-resistant (MDR) Gram-negative pathogens as the

138 of new and 18% of recurrent cases of TB are multidrug-resistant (MDR) or rifampicin-resistant.

139 stance is lacking in LMICs, particularly for multidrug-resistant (MDR) pathogens.

140 Multidrug-resistant (MDR) Salmonella enterica has been d

141 Among 36 patients with multidrug-resistant (MDR) TB who had a sediment specimen

142 rthermore, 50% of the recovered strains were multidrug-resistant (MDR) to penicillins, cephalosporins

143 porin with activity against a broad array of multidrug-resistant (MDR), aerobic Gram-negative bacilli

144 dant as powerful antibacterial agent against multidrug-resistant (MDR), biofilm-forming E. coli.

145 We evaluated the accuracy of the BD MAX multidrug-resistant (MDR)-TB assay (BD MAX) in South Afr

146 gene acquisition, and two that were largely multidrug-resistant (MDR).

147 We have previously observed that multidrug-resistant 2 (Mdr2(-/-) ) double knockout (DKO)

148 phenicol, and trimethoprim-sulfamethoxazole (multidrug-resistant [MDR]).

149 Indeed, multidrug-resistant A. baumannii is a major cause of hos

150 ith broad-spectrum in vitro activity against multidrug-resistant and extensively drug-resistant bacte

151 are under threat because of the emergence of multidrug-resistant and extensively drug-resistant tuber

152 ibits in vivo efficacy against a challenging multidrug-resistant and vancomycin-resistant S. aureus s

153 he surface of the ETT and the development of multidrug-resistant bacteria are considered the primary

154 Since the emergence of deadly pathogens and multidrug-resistant bacteria at an alarmingly increased

155 Multidrug-resistant bacteria pose a serious health threa

156 ive MAC transfer leads to the elimination of multidrug-resistant bacteria, including Staphylococcus a

157 that they kill clinical isolates of several multidrug-resistant bacteria-including those from the ge

158 vides an alternative strategy for overcoming multidrug-resistant bacteria-induced sepsis and opens up

159 s (MACs) can be applied for the treatment of multidrug-resistant bacteria-induced sepsis in mice with

160 ion as new drugs or drug adjuvants to combat multidrug-resistant bacteria.

161 n proposed as an alternative therapy against multidrug-resistant bacteria.

162 s and contributes to increased prevalence of multidrug-resistant bacteria.

163 noglycoside antibiotics for the treatment of multidrug-resistant bacterial infections, particularly t

164 y tract and respiratory infections caused by multidrug-resistant bacterial pathogens, a serious publi

165 ntibacterial drugs to combat infections with multidrug-resistant bacterial pathogens.

166 s in the 2016 to 2018 multistate outbreak of multidrug-resistant C. jejuni Here, we aimed to elucidat

167 report the isolation of 2 clonal lineages of multidrug-resistant Campylobacter coli from MSM in Seatt

168 previously reported that some, but not all, multidrug-resistant cells that overexpressed various dru

169 sal drug-susceptible bacteria to evolve into multidrug-resistant clones that are able to successfully

170 A multidrug-resistant co-lineage of Plasmodium falciparum

171 port the first case of belatacept-associated multidrug-resistant Cytomegalovirus retinitis in a kidne

172 ce of antimicrobial resistant phenotypes and multidrug-resistant E coli carriage in urban wildlife is

173 amined factors associated with the spread of multidrug-resistant E. coli phenotypes responsible for d

174 antibiotic resistome, prolonged carriage of multidrug-resistant Enterobacteriaceae and distinct anti

175 arenteral aminoglycoside developed to target multidrug-resistant Enterobacteriaceae.

176 (phages), that could be harnessed to combat multidrug-resistant enterococcal infections.

177 Multidrug-resistant Enterococcus faecalis, an opportunis

178 we measured the recombination parameters of multidrug-resistant Escherichia coli ST131.

179 ty to inhibit growth of clinical isolates of multidrug-resistant ESKAPE pathogens.

180 Candida auris, a multidrug-resistant fungal pathogen, is responsible for

181 gainst strains of Candida auris, an emerging multidrug-resistant fungus that presents a serious globa

182 nterventions and includes C. auris, a highly multidrug-resistant fungus.

183 concern with respect to the transmission of multidrug-resistant gastrointestinal pathogens and the r

184 -Leg5,7Ac(2) was efficacious against several multidrug-resistant gonococci in mice with a humanized s

185 Novel therapies to counteract multidrug-resistant gonorrhea are urgently needed.

186 Multidrug-resistant Gram-negative (GN) infections for wh

187 Patients with multidrug-resistant gram-negative bacilli (MDR-GNB), acc

188 vancomycin-resistant enterococci (P = .008), multidrug-resistant gram-negative bacteria (P = .016), o

189 in antibiotics are a last-line treatment for multidrug-resistant Gram-negative bacteria.

190 or treatment of serious infections caused by multidrug-resistant gram-negative bacteria.

191 the treatment of human infections caused by multidrug-resistant Gram-negative bacteria.

192 to have a wide spectrum of activity against multidrug-resistant Gram-negative bacteria; however, bre

193 baumannii is an opportunistic and frequently multidrug-resistant Gram-negative bacterial pathogen tha

194 Treatment of multidrug-resistant Gram-negative bacterial pathogens re

195 (polymyxin B and colistin) for treatment of multidrug-resistant Gram-negative infections, many clini

196 antimicrobials with potent activity against multidrug-resistant gram-negative pathogens, such as car

197 The cadasides inhibit the growth of multidrug-resistant Gram-positive pathogens by disruptin

198 pibrentasvir was also effective in clearing multidrug-resistant HCV replication in mice.

199 l in 23 countries, we enrolled patients with multidrug-resistant HIV-1 infection in two cohorts, acco

200 In patients with multidrug-resistant HIV-1 infection with limited therapy

201 avily treatment-experienced individuals with multidrug-resistant HIV-1.

202 spital outbreaks and the recent emergence of multidrug-resistant hypervirulent strains.

203 Pseudomonas aeruginosa causes severe multidrug-resistant infections that often lead to bacter

204 and are acutely vulnerable to the threat of multidrug-resistant infections.

205 ly, we identified several hundred genes in a multidrug-resistant isolate of Acinetobacter baumannii t

206 flagged such as cross-resistance against the multidrug-resistant K1 strain, in vitro cytotoxicity, an

207 lo-beta-lactamase (NDM)-producing strains of multidrug-resistant Klebsiella pneumoniae are a global p

208 The well-described multidrug-resistant lineage is associated with high rate

209 RT) constitutes a promising target to combat multidrug-resistant malaria.

210 Multidrug-resistant Mycobacterium tuberculosis (MDR-TB)

211 rapeutic agents against the global threat of multidrug-resistant N. gonorrhoeae.

212 ins, which are responsible for the burden of multidrug-resistant nontyphoidal invasive disease in Afr

213 f healthcare personnel hand contamination in multidrug-resistant organism (MDRO) transmission is impo

214 re used to compare changes in hospital-onset multidrug-resistant organism bloodstream infection (MDRO

215 A-) Antibiotic Resistant Organisms (ARO) and Multidrug-Resistant Organisms (MDRO).

216 The extent to which donor multidrug-resistant organisms (MDROs) affect organ utili

217 peritonitis (SBP) in patients colonized with multidrug-resistant organisms (MDROs) is unknown.

218 A) antibiotic-resistant organisms (AROs) and multidrug-resistant organisms (MDROs).

219 health response to contain novel or targeted multidrug-resistant organisms (MDROs).

220 ling of healthcare-associated infections and multidrug-resistant organisms improves our understanding

221 lude inadequate source control, treatment of multidrug-resistant organisms, and pharmacokinetic alter

222 ulnerable to colonization and infection with multidrug-resistant organisms, including vancomycin-resi

223 To address the growing threat of multidrug-resistant organisms, policymakers are seeking

224 coccus aureus and cryptococcosis, as well as multidrug-resistant organisms.

225 se loci were in linkage equilibrium and that multidrug-resistant parasites have not expanded in this

226 penem-resistant Enterobacteriaceae (CRE) are multidrug-resistant pathogens for which new treatments a

227 is thought to contribute to the emergence of multidrug-resistant pathogens through horizontal gene tr

228 tibacterial drugs that are effective against multidrug-resistant pathogens.

229 methyltransferases (Erms), rMtases found in multidrug-resistant pathogens.

230 el antibiotics are urgently needed to combat multidrug-resistant pathogens.

231 s of antibiotics to 23S rRNA, resulting in a multidrug-resistant phenotype in bacteria expressing the

232 R genes and plasmids, including an identical multidrug-resistant plasmid isolated from both S. sonnei

233 The emergence and spread of multidrug-resistant Plasmodium falciparum in the Greater

234 Multidrug-resistant Plasmodium falciparum undermines the

235 e was a 26.0% (95% CI 17.7-33.0) decrease in multidrug-resistant pneumococcal colonization.

236 ing, we characterized genomic variability of multidrug-resistant Rhodococcus equi isolated from soil

237 rs with clinically-relevant activity against multidrug-resistant S. aureus.

238 xposure and travel to describe the spread of multidrug-resistant Shigella lineages.

239 s, including globally distributed strains of multidrug-resistant Shigella species.

240 en, with most bacteria belonging to pandemic multidrug-resistant ST131-H30R or ST1193 clonal groups.

241 The multidrug-resistant Staphylococcus capitis NRCS-A clone

242 Phylogenetics identified multidrug-resistant strains as being widely distributed

243 linical isolates of N. gonorrhoeae including multidrug-resistant strains at a concentration as low as

244 s previously reported for Shigella, specific multidrug-resistant strains of Campylobacter are circula

245 s previously reported for Shigella, specific multidrug-resistant strains of Campylobacter are circula

246 f healthcare-associated infections caused by multidrug-resistant strains producing extended-spectrum

247 ome active against pathogenic Clostridia and multidrug-resistant strains.

248 -TB treatment indicated an increased risk of multidrug-resistant TB (MDR-TB) emerging (8%), compared

249 is recommended in short-course regimens for multidrug-resistant TB (MDR-TB).

250 n a multicountry prospective cohort study of multidrug-resistant TB, we identified inhA, katG, and rp

251 ; 95% confidence interval, 0.18-0.48) and to multidrug-resistant tuberculosis (adjusted hazard ratio,

252 fumarate as part of combination therapy for multidrug-resistant tuberculosis (MDR TB).

253 part of combination therapy for treatment of multidrug-resistant tuberculosis (MDR TB).

254 manid are newly available drugs for treating multidrug-resistant tuberculosis (MDR TB); however, ther

255 ousehold contacts (HHCs) of individuals with multidrug-resistant tuberculosis (MDR-TB) are at high ri

256 We assessed multidrug-resistant tuberculosis (MDR-TB) cases and thei

257 PZA resistance in multidrug-resistant tuberculosis (MDR-TB) is common and

258 ion (WHO) recommended a shorter (9-12 month) multidrug-resistant tuberculosis (MDR-TB) treatment regi

259 tion as the preferred option in treatment of multidrug-resistant tuberculosis (MDR-TB) with long regi

260 manid are newly available drugs for treating multidrug-resistant tuberculosis (MDR-TB); however, ther

261 Approximately 50% of multidrug-resistant tuberculosis and over 90% of extensi

262 327 patients were culture-positive for multidrug-resistant tuberculosis at baseline and compris

263 The emergence and expansion of the multidrug-resistant tuberculosis epidemic is a threat to

264 rolonged (ie, 9-24 months) and patients with multidrug-resistant tuberculosis have less favourable ou

265 eview what we know about the transmission of multidrug-resistant tuberculosis in settings with high b

266 may have a role in the management of latent multidrug-resistant tuberculosis infection.

267 18 years or older with confirmed or presumed multidrug-resistant tuberculosis initiating tuberculosis

268 A case of multidrug-resistant tuberculosis is presented.

269 Treatment for patients with multidrug-resistant tuberculosis is prolonged (ie, 9-24

270 Multidrug-resistant tuberculosis is the result of the se

271 We included 11 920 multidrug-resistant tuberculosis patients.

272 rug-resistant tuberculosis and patients with multidrug-resistant tuberculosis that was not responsive

273 tching on age, sex, geographic site, year of multidrug-resistant tuberculosis treatment initiation, p

274 s associated with increased mortality during multidrug-resistant tuberculosis treatment, but the exte

275 V-negative patients in terms of death during multidrug-resistant tuberculosis treatment, excluding th

276 ic nitroimidazole, was recently approved for multidrug-resistant tuberculosis treatment.

277 ations within lung cavities of patients with multidrug-resistant tuberculosis undergoing therapeutic

278 ey had been exposed to an index patient with multidrug-resistant tuberculosis.

279 ds of death among HIV-positive patients with multidrug-resistant tuberculosis.

280 d mortality risk in HIV-positive adults with multidrug-resistant tuberculosis.

281 tly approved medication for the treatment of multidrug-resistant tuberculosis.

282 ive therapy on the contacts of patients with multidrug-resistant tuberculosis.Methods: In a prospecti

283 s, including lung metastatic tumors and even multidrug-resistant tumors.

284 Candida auris is a multidrug-resistant yeast associated with hospital outbr

285 Candida auris is an emerging multidrug-resistant yeast that has been systematically i

286 Candida auris is a multidrug-resistant yeast which has emerged in health ca

287 017, a patient presented colonization with a multidrug-resistant, carbapenemase (KPC-3)-producing Kle

288 an international collection of the emerging, multidrug-resistant, opportunistic pathogen Stenotrophom

289 t acquisitions of extensively drug-resistant/multidrug-resistant-inducing plasmids, probably facilita

290 e rates, even with treatment by the on-going multidrug therapy (MDT).

291 Leprosy has been treated with multidrug therapy, which has been distributed for free a

292 CG2 has been resolved, and the mechanisms of multidrug transport remain obscure.

293 ichia coli is a prototypical H(+) -dependent multidrug transporter belonging to the Major Facilitator

294 thin Lactococcus lactis LmrP, a prototypical multidrug transporter of the major facilitator superfami

295 Multidrug transporters can confer drug resistance on cel

296 exity, the mechanism of Hoechst transport by multidrug transporters is poorly characterised.

297 Multidrug transporters prompt multidrug resistance by ex

298 ecificity of this protein and possibly other multidrug transporters.

299 may further improve the feasibility of this multidrug treatment for patients with advanced pancreati

300 ctious agent, requiring at least 6 months of multidrug treatment to achieve cure(1).